Clinical Trial Update: A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101 [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety and tolerability of two concentrations of QLS-101 in Sturge-Weber syndrome and glaucoma-related conditions has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Glaucoma
• Glaucoma
• Ocular Hypertension
• Sturge-weber Syndrome

Drugs mentioned

• QLS-101

Snippet

Sponsor: Qlaris Bio, Inc. | Conditions: Sturge-Weber Syndrome (SWS), Glaucoma | Phase 2 | Status: COMPLETED